{"id":"las41007","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting PDE4, the drug prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated intracellular cAMP concentrations. This suppresses the production of pro-inflammatory cytokines and chemokines from immune cells, thereby reducing inflammation. The mechanism is particularly relevant for inflammatory and immune-mediated diseases.","oneSentence":"LAS41007 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:27.513Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT00991861","phase":"PHASE2","title":"Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2009-08","conditions":"Actinic Keratosis","enrollment":100},{"nctId":"NCT01265602","phase":"PHASE3","title":"Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2010-11","conditions":"Actinic Keratosis","enrollment":889}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LAS41007","genericName":"LAS41007","companyName":"Almirall, S.A.","companyId":"almirall-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LAS41007 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Atopic dermatitis, Psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}